APA (7th ed.) Citation

A, T., B, M., C, S., R, M., & MP, A. (2018). Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention. Vaccine, 36(9), 1235. https://doi.org/10.1016/j.vaccine.2017.11.032

Chicago Style (17th ed.) Citation

A, Thiam-Diouf, Metch B, Sharpe C, Mulugeta R, and Andrasik MP. "Substance Use Patterns of HVTN Phase I Clinical Trial Participants: Enrollment, Risk Reduction Counseling and Retention." Vaccine 36, no. 9 (2018): 1235. https://doi.org/10.1016/j.vaccine.2017.11.032.

MLA (9th ed.) Citation

A, Thiam-Diouf, et al. "Substance Use Patterns of HVTN Phase I Clinical Trial Participants: Enrollment, Risk Reduction Counseling and Retention." Vaccine, vol. 36, no. 9, 2018, p. 1235, https://doi.org/10.1016/j.vaccine.2017.11.032.